Perceptive Advisors LLC Inhibrx, Inc. Transaction History

Perceptive Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$15.75 - $26.31 $9.95 Million - $16.6 Million	631,922 Added 17.44%	4,256,104 $78.1 Million
Q2 2023 Aug 14, 2023	BUY	$16.96 - $27.82 $149,231 - $244,788	8,799 Added 0.24%	3,624,182 $94.1 Million
Q1 2023 May 15, 2023	BUY	$18.45 - $27.14 $5.56 Million - $8.19 Million	301,600 Added 9.1%	3,615,383 $68.2 Million
Q4 2022 Feb 14, 2023	BUY	$20.18 - $33.33 $8.6 Million - $14.2 Million	425,923 Added 14.75%	3,313,783 $81.7 Million
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $11.3 Million - $24.1 Million	973,268 Added 50.83%	2,887,860 $51.8 Million
Q2 2022 Aug 15, 2022	BUY	$8.52 - $25.26 $1.14 Million - $3.37 Million	133,357 Added 7.49%	1,914,592 $21.7 Million
Q1 2022 May 16, 2022	BUY	$19.89 - $43.18 $8.71 Million - $18.9 Million	437,745 Added 32.58%	1,781,235 $39.7 Million
Q4 2021 Feb 14, 2022	BUY	$26.75 - $46.02 $5.94 Million - $10.2 Million	222,000 Added 19.8%	1,343,490 $58.7 Million
Q3 2021 Nov 15, 2021	BUY	$25.18 - $37.81 $5.4 Million - $8.11 Million	214,400 Added 23.64%	1,121,490 $37.4 Million
Q2 2021 Aug 16, 2021	BUY	$14.69 - $27.52 $13.3 Million - $25 Million	907,090 New	907,090 $25 Million

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.